Clinical trial
OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease
NCT07486206 is registered in ClinicalTrials.gov with Hospital de Granollers as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- OPTIMIZE-ILD-2: A Randomized, Pragmatic, Parallel-Group Trial Evaluating the Impact of an Optimized Coordinated Follow-Up Circuit on Time Burden in Patients With Interstitial Lung Disease
- Lead sponsor
- Hospital de Granollers
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- March 9, 2026
- Completion date
- March 1, 2028
- Enrollment
- 152 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
fibrotic interstitial lung disease, idiopathic pulmonary fibrosis (ipf), interstitial lung disease (ild), interstitial lung disease due to connective tissue disease (disorder), progressive pulmonary fibrosis